Tag: Microgen

Microgen – Russian pharmaceutical company.

Federal State Scientific-Industrial Company MICROGEN is the largest company in Russian medical industry that holds leadership in development and production of immunobiological preparations, diagnosticums and drugs.

Consortium MICROGEN was founded in May, 2003 in order to create a competitive enterprise in the field of medical immunobiology that could ensure the implementation of national programs of biological and epidemiological security, development of domestic biotechnological industry in accordance with international standards of drug production and practical application of new and highly effective preparations.

Subsidiaries that were amalgamated within the MICROGEN have a history that is more than a hundred years long. They were created on the basis of Pasteur centers and laboratories that conducted studies in the field of immunobiology.

At present Federal State Scientific-Industrial Company MICROGEN is a modern enterprise that holds leadership position in the domestic pharmaceutical industry. Production output for MICROGEN in the year 2013 was more than US$150m.

The company steadily widens the shipping geography of its immunobiological products: they go to the CIS countries (Kazakhstan, Ukraine, Byelorussia, Uzbekistan, Azerbaijan, Armenia, Georgia), Mexico, Mongolia, Vietnam, India. A number of countries of Africa, South-East Asia and Latin America are conducting talks concerning future cooperation.

MICROGEN Consortium in active cooperation with leading Russian and foreign research centers is working on designing and application to production development of the unique innovations in immunobiology and biotechnology.

In collaboration with leading Russian scientists the company is striving to develop and manufacture new high-quality preparations, modern pharmaceutical forms.

MICROGEN specialists participate in international research projects including WHO programs for eradication of natural smallpox, measles, rubella, tuberculosis, whooping cough, diphtheria, tetanus, avian flu, etc.

At present more than 15 novel preparations are being prepared for commercial production, e.g. new influenza, smallpox and tick-borne encephalitis vaccines, associated DTP vaccine, hepatitis B vaccine, hemophilic infection vaccine, mumps, measles and rubella vaccine, avian flu vaccine, cell-depleted pertussis vaccine, staphylococcal-proteus-pseudomonas aeruginosa vaccine (SPPA-vaccine) and others.

Russian botulinum toxin confirmed its compliance with quality requirements

Relatox, the first and only one Russian-made botulinum toxin manufactured by Nacimbio holding company, a part of Rostec Corporation confirmed its compliance with the requirements of the state expert e...

Nacimbio produce more than 70% of required immunization medicines

National Immunobiological Company presented its immunobiological products at all-Russian forum and exhibition "State Order – For Fair Procurement". Nacimbio plants produce more than 70% of the volume ...

Nacimbio starts clinical trials of the first Russian meningococcal vaccine

clinical trial
NPO Microgen, part of the National Immunobiological Company, has begun Phase I clinical trials of the first Russian polysaccharide meningococcal vaccine against serotypes A and C. The preclinical stud...

Microgen is ready to market a unique bacteriophage

Combined bacteriophage preparation "Enterobacter multivalent purified" intended for treatment and prevention of infections caused by Enterobacter species has successfully passed the phase II clinical ...

Medicines of the XXI century

The cytomedines production site, filling and capping line. Research and production association (NPO) "Microgen", a branch in Ufa, the company "Immunopreparat"
Report from the cytomedines production site of pharmaceutical company "Immunopreparat". Many of us have heard about cytomedines - a special class of medicines, the peptide bioregulators. They carry t...